Product image of Mensinorm Set (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Mensinorm Set

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Mensinorm Set (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle‑Stimulating Hormone and Luteinising Hormone, the active ingredients in Mensinorm Set, are gonadotropins presented as an injectable solution for intramuscular or subcutaneous use. They stimulate ovarian follicle development, estrogen synthesis and ovulation, and are indicated for induction of ovulation and controlled ovarian stimulation in women experiencing infertility.

GNH India supplies Mensinorm Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU manufacturing standards and provides cold‑chain logistics for the injectable product.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mensinorm Set, a gonadotropin therapy, is used in reproductive medicine to support ovarian stimulation.

  • Induction of ovulation: facilitates follicular growth and ovulation in women with anovulatory infertility.
  • Controlled ovarian stimulation: enables development of multiple follicles for assisted reproductive technologies such as in‑vitro fertilisation.
  • Polycystic ovary syndrome (PCOS) ovulation induction: promotes ovulation in PCOS patients undergoing fertility treatment.

How It Works

  • Mensinorm Set contains recombinant Follicle‑Stimulating Hormone and Luteinising Hormone that bind to their respective receptors on granulosa and theca cells of ovarian follicles. Activation of the FSH receptor drives follicular proliferation and aromatase activity, increasing estradiol production, while LH receptor activation supports theca‑cell androgen synthesis and final follicular maturation, together leading to ovulation.

Side Effects

Adverse reactions to Mensinorm Set may vary in frequency and severity.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the administration site.
  • Abdominal discomfort: transient bloating or mild pain.
  • Nausea or vomiting: occasional gastrointestinal upset.
  • Headache: mild to moderate intensity.
  • Breast tenderness: temporary soreness.
  • Mild ovarian hyperstimulation syndrome: mild abdominal distension and fluid shift.

Serious or Rare Side Effects

  • Severe ovarian hyperstimulation syndrome: marked abdominal pain, rapid weight gain, and respiratory distress.
  • Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
  • Allergic reactions or anaphylaxis: rash, urticaria, bronchospasm.
  • Multiple pregnancy: higher-order gestations.
  • Ovarian torsion: acute pelvic pain requiring surgical intervention.
  • Ectopic pregnancy: implantation outside the uterus.

Precautions & Warnings

Prior to using Mensinorm Set, clinicians should consider several safety measures.

  • Pregnancy testing: confirm non‑pregnant status before initiating therapy.
  • Ovarian monitoring: perform serial ultrasound to assess follicular response.
  • Risk of OHSS: monitor for signs of ovarian hyperstimulation syndrome, especially in high responders.
  • Allergy assessment: evaluate for hypersensitivity to gonadotropins or excipients.
  • Thromboembolic risk: consider patient history of clotting disorders before treatment.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mensinorm Set may interact with other agents that influence ovarian response or coagulation.

Major Interactions (Avoid)

  • GnRH agonists: may increase risk of severe ovarian hyperstimulation when combined.
  • Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy of Mensinorm Set.
  • Clomiphene citrate: overlapping mechanisms can cause excessive ovarian stimulation.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: monitor clotting parameters if OHSS develops.
  • Thyroid hormone therapy: adjust dosing if thyroid dysfunction is present.
  • Insulin or other diabetes medications: observe glucose fluctuations during OHSS‑related fluid shifts.

Frequently Asked Questions

Mensinorm Set is a gonadotropin preparation used to induce ovulation and to provide controlled ovarian stimulation in women undergoing fertility treatment, including assisted reproductive technologies such as in‑vitro fertilisation.

The two hormones bind to specific receptors on ovarian granulosa and theca cells. FSH promotes follicular growth and estrogen production, while LH supports androgen synthesis and final maturation of the dominant follicle, together leading to ovulation.

The dose is individualized by the prescribing clinician based on the patient’s ovarian response, body weight, age, and treatment protocol. No fixed regimen is provided; dosing is adjusted according to ultrasound monitoring and hormone levels.

Mensinorm Set is intended for use before conception to achieve ovulation. Its safety in established pregnancy or while breastfeeding has not been established, and it is generally not recommended in those situations.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mensinorm Set combines recombinant FSH and LH in a single injectable formulation, offering coordinated follicular stimulation. Compared with single‑component products, it may reduce the number of injections needed, but clinical choice depends on individual patient response and physician preference.

Store the vials at 2‑8 °C in a refrigerator, protect them from light, and avoid freezing or shaking. Use aseptic technique for reconstitution and administration, and discard any solution that appears discolored or particulate.

Mensinorm Set is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The prescriber determines the injection site, volume and frequency, which are typically administered by a trained healthcare professional in a clinical setting.

The most serious risks include severe ovarian hyperstimulation syndrome, thromboembolic events, allergic reactions such as anaphylaxis, ovarian torsion, and the possibility of multiple or ectopic pregnancy. Prompt medical attention is required if any of these occur.

Mensinorm Set should be avoided in women with known hypersensitivity to gonadotropins, uncontrolled thyroid disease, active ovarian cysts, severe ovarian failure, or a history of thromboembolic disorders. It is also contraindicated in pregnancy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT